Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Bartsch

Showing results (1-10 of 228) with videos related to

Pageof 23
Sort By:
Memo|May 10, 2021
ESMO 2020: highlights in breast cancerRupert Bartsch
Expert Opinion on Investigational Drugs|July 24, 2020
Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancerRupert Bartsch
ESMO Open|January 6, 2018
Ribociclib: a valuable addition to treatment options in breast cancer?Rupert Bartsch
Memo|June 28, 2021
European Society for Medical Oncology 2020Rupert Bartsch
Memo|July 5, 2021
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancerRupert Bartsch
Memo|June 13, 2022
COVID-19 crisis and cancerRupert Bartsch, Wolfgang Hilbe
Memo|December 19, 2017
ASCO 2017: highlights in breast cancerRupert Bartsch, Elisabeth Bergen
Memo|September 18, 2018
SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapyRupert Bartsch, Elisabeth Bergen
Memo|January 7, 2017
ASCO 2016: highlights in breast cancerRupert Bartsch, Elisabeth Bergen
Breast Care (Basel, Switzerland)|January 2, 2023
Evolution of HER2 Targeting in Metastatic Breast CancerRupert Bartsch, Marija Balic
Pageof 23

Showing results (1-10 of 228) with videos related to

Sort By:
Pageof 23
Memo|May 10, 2021
ESMO 2020: highlights in breast cancerRupert Bartsch
Expert Opinion on Investigational Drugs|July 24, 2020
Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancerRupert Bartsch
ESMO Open|January 6, 2018
Ribociclib: a valuable addition to treatment options in breast cancer?Rupert Bartsch
Memo|June 28, 2021
European Society for Medical Oncology 2020Rupert Bartsch
Memo|July 5, 2021
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancerRupert Bartsch
Memo|June 13, 2022
COVID-19 crisis and cancerRupert Bartsch, Wolfgang Hilbe
Memo|December 19, 2017
ASCO 2017: highlights in breast cancerRupert Bartsch, Elisabeth Bergen
Memo|September 18, 2018
SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapyRupert Bartsch, Elisabeth Bergen
Memo|January 7, 2017
ASCO 2016: highlights in breast cancerRupert Bartsch, Elisabeth Bergen
Breast Care (Basel, Switzerland)|January 2, 2023
Evolution of HER2 Targeting in Metastatic Breast CancerRupert Bartsch, Marija Balic
Pageof 23